Vabysmo:
US: ~30% naive patients, ~70% switches (mostly from aflibercept);
US market share reaches 15% in nAMD and 9% in DME;
发布于: | 雪球 | 转发:1 | 回复:3 | 喜欢:0 |
Vabysmo:
US: ~30% naive patients, ~70% switches (mostly from aflibercept);
US market share reaches 15% in nAMD and 9% in DME;
长效eylea延期巨伤